NCT04856085CompletedPhase 2
Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection
A Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of Regimens Containing VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection
Source: ClinicalTrials.gov · Last updated 23 Apr 2026
Brief summary (registry, in English)
This is a phase 2 study in which participants with chronic hepatitis B virus (HBV) infection will receive VIR-2218, VIR-3434 and/or PEG-IFNα and be assessed for safety, tolerability, and efficacy
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 244 (actual)
- First submitted
- 21 Apr 2021
- Start date
- 11 Jul 2021
- Primary completion date
- 16 Mar 2026
- Lead sponsor
- Vir Biotechnology, Inc.
- Diseases
- Hepatitis B
- NCT number
- NCT04856085
- EU CT number
- 2024-513177-48-00
- EudraCT number
- 2021-001033-39
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 244
- From 11 Jul 2021 to the primary completion date, 16 Mar 2026
- 30 sites in 12 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- History or evidence of drug or alcohol abuse
Other illness
- Any clinically significant chronic or acute medical condition that makes the participant unsuitable for participation
- History of chronic liver disease from any cause other than chronic HBV infection
- History of hepatic decompensation
- History of anaphylaxis
- History of allergic reactions, hypersensitivity, or intolerance to monoclonal antibodies, antibody fragments, or any excipients of VIR-3434
- History of immune complex disease
- History of known contraindication to any interferon product
Other
- Significant fibrosis or cirrhosis
Who the study is looking for
- Male or female ages 18 - \<66 years
- Chronic HBV infection for \>/= 6 months
- On NRTI therapy for \>/= 2 months at the time of screening
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (30)
Sites in registry order. Pick your city on the disease page to sort them by distance.
Related publications
- Combination therapy with tobevibart and elebsiran potently reduces hepatitis B virus surface antigen levels in preclinical in vivo models.Antimicrob Agents Chemother · 2026 · PMID 41586499
This page is information, not medical advice. Discuss any trial with your doctor.